Herpes zoster como efeito colateral do tratamento da leishmaniose tegumentar americana com antimonial pentavalente

Detalhes bibliográficos
Ano de defesa: 2009
Autor(a) principal: Barros, Andrea Barbieri de
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal de Mato Grosso
Brasil
Faculdade de Medicina (FM)
UFMT CUC - Cuiabá
Programa de Pós-Graduação em Ciências da Saúde
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Link de acesso: http://ri.ufmt.br/handle/1/6426
Resumo: Cutaneous leishmaniasis is an endemic disease that affects a significant number of people each year around the world. The first-line treatment is based on the use of antimony drugs. This group of drugs has several adverse effects. Recently, varicella-zoster vírus reactivation has been reported in isolated casesand related to leishmaniais treatiment wich pentavalent antimonials. This study describes 16 patients who had herpes zoster during or shortly after the use of antimony. Among them, 15 (93.8%) were male, with median (range) of 53.3 (22-81) years. Most (75%) had herpes zoster related to meglumine antimoniate and 25% to sodium stibogluconate. The median (range) of onset of herpes zoster lesions was 22.1 (8-36) days. No differences were observed between the two compounds on the dose administered or the time of onset of herpetic lesions. Itcan be concluded that the treatment of tegumentary leishmaniasis withpentavalent antimony, including meglumine antimoniate, is associated with the occurrence of reactivation of varicella-zoster virus. This complication may occur during or after several days of the medication interruption.